REG - AstraZeneca PLC - Agreement with US Govt to lower medicine prices

AstraZenecaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251013:nRSM9729Ca&default-theme=true

RNS Number : 9729C  AstraZeneca PLC  13 October 2025

13 October 2025

 

AstraZeneca announces historic agreement with US Government to lower the cost
of medicines for American patients

Delivers on all four of President Trump's requests reducing cost of medicines

Preserves America's role as a global powerhouse in biopharmaceuticals
innovation

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic
sourcing

AstraZeneca today announces a historic agreement with President Donald J.
Trump's administration to lower the cost of prescription medicines for
American patients while preserving America's cutting-edge biopharmaceutical
innovation.

 

At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined
President Trump and members of his Administration to confirm the Company
voluntarily met all requests set out in the President's 31 July letter. The
Company agrees to a range of measures which will enable American patients to
access medicines at prices that are equalized with those available in wealthy
countries.

 

As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC)
sales to eligible patients with prescriptions for chronic diseases at a
discount of up to 80% off list prices. AstraZeneca will participate in the
TrumpRx.gov direct purchasing platform, which will allow patients to purchase
medicines at a reduced cash price from AstraZeneca.

 

AstraZeneca has also reached an agreement with the US Department of Commerce
to delay Section 232 tariffs for three years, enabling the Company to fully
onshore medicines manufacturing so that all of its medicines sold in America
are made in America. This will be achieved through the Company's recently
announced $50 billion investment
(https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html)
in US medicines manufacturing and R&D over the next five years to help
deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be
generated in the US.

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Every year
AstraZeneca treats millions of Americans living with cancer and chronic
diseases and, as a result of today's agreement, many patients will access
life-changing medicines at lower prices. This new approach also helps
safeguard America's pioneering role as a global powerhouse in innovation and
developing the next generation of medicines. It is now essential other wealthy
countries step up their contribution to fund innovation."

 

AstraZeneca's commitment to the US and American patients is further reflected
in the Company's largest single investment in a manufacturing facility to
date, where the Company broke ground yesterday in Virginia. This facility will
support AstraZeneca's weight management and metabolic portfolio and our
leading antibody drug conjugate cancer pipeline. Additionally, a newly
expanded manufacturing facility in Coppell, Texas, will officially open next
week. Looking ahead, AstraZeneca will open a cell therapy manufacturing
facility in Rockville, Maryland early next year and its second major R&D
centre in Cambridge, Massachusetts will open in late 2026.

 

The US is AstraZeneca's largest market by sales and is also home to 19
R&D, manufacturing and commercial sites. The Company's US workforce
exceeds more than 25,000 people and supports more than 100,000 jobs overall
across the country. In 2025, AstraZeneca created approximately $20 billion of
overall value to the American economy.

 

Notes

 

AstraZeneca's agreement with US Government

This is the second agreement that a pharmaceutical company has made with the
US Department of Health and Human Services to lower the cost of medicines for
American patients in the past two weeks. Specific terms of this agreement
remain confidential.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
. The contents of AstraZeneca's website do not form part of this document and
no one should rely on such websites or the contents thereof in reading this
document.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFLFEVIALILIE



            Copyright 2019 Regulatory News Service, all rights reserved